T-Cell Lymphoma
The latest news, research, and perspectives in T-cell lymphoma. Most T-cell lymphomas are non-Hodgkin lymphomas that develop from mature T cells. The most common subtypes include mycosis fungoides, anaplastic large-cell lymphoma, and precursor T-lymphoblastic lymphoma.
Advertisement
Advertisement
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
Based on promising results from the phase II TELLOMAK study, the FDA grants a breakthrough therapy designation for lacutamab.
Researchers have developed a new scoring system using one of the largest global cohorts of T-cell lymphoma patients.
Therapy also in development for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.
The therapies are under development for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus.
Relmacabtagene autoleucel is an anti-CD19 chimeric antigen receptor T-cell product
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
A database study has identified an association between disease stage at lymphoma diagnosis and time of Medicaid enrollment.
Results from the phase 1 ENABLE-1 study show complete responses comparable to commercial CAR Ts in B-cell NHL.
Limitations on benefits from immunotherapy in this setting increase clinical interest in this CAR T-cell therapy approach.
Diagnosis is challenging due to the high variety of origin cell types, clinical manifestations, genetics, and histology.
Efficacy was evaluated specifically in PTCL and safety in PTCL along with adult T-cell leukemia or lymphoma.
The study used CRISPR screening to identify susceptibility markers for brentuximab vedotin in CD30-positive PTCLs.
Consensus clinical practice recommendations regarding use of this potentially curative procedure had previously been absent.
Recent advances in knowledge about PTCL biology help inform clinical trial design and use of precision therapy.
Co-authors of a new review article suggest other factors more strongly influence secondary tumor development.
A single-center study compared the secondary and initial tumors and assessed vector viral integration's role in oncogenesis.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Advertisement
Section Editor
Nora Bennani, MDAssistant Professor of Medicine at Mayo Clinic
Advertisement
Latest News
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.